Li Li

Dr. Li Li

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YBYaning Biao
Yaning Biao
JCJian Chen
Jian Chen
CLChenxu Liu
Chenxu Liu
RWRuilong Wang
Ruilong Wang
XHXue Han
Xue Han
ZYZhang Yi-xin
Zhang Yi-xin
Lipid metabolism disorders are a prominent characteristic in the pathological development of non-alcoholic fatty liver disease (NAFLD). Danshen zexie decoction (DZD) is a Chinese herbal medicine that is based on zexie decoction and has an effect of regulating lipid mechanism. However, the anti-NAFLD effect and mechanism of DZD remain unclear. In this study, we observed the therapeutic effect of DZD on NAFLD rats and investigated its possible mechanisms. Sixty Sprague Dawley rats were randomly assigned to six groups: control group, model group, Yishanfu (polyene phosphatidylcholine) group, and low, medium and high-dose DZD groups. High-fat diet (HFD) was fed to the rats to establish an NAFLD model, and each treatment group was given corresponding drugs at the same time for eight consecutive weeks. The results revealed that the obvious lipid metabolism disorder and liver injury induced by HFD were alleviated by treatment with DZD, which was verified by decreased serum TC, TG, ALT, AST, liver TC, TG, and FFA, as well as the alleviation of hepatic steatosis. The production of ROS in rats was reduced after treatment with DZD. The SOD activity and GSH content were increased with DZD treatment, while the MDA level was decreased. The administration of DZD could decrease serum IL-1β and IL-18 contents. Moreover, DZD upregulated the expressions of Nrf2, HO-1, GCLC, and GCLM, while it suppressed the expressions of NLRP3, caspase-1, GSDMD, and GSDMD-N. In conclusion, the data showed that DZD can reduce lipid accumulation, alleviate oxidative stress and inflammation, and inhibit pyroptosis in NAFLD rats, which might be ascribed to suppression of the ROS/NLRP3/IL-1β signaling pathway by activation of Nrf2. Overall, these results indicated that DZD is expected to be a therapeutic drug for NAFLD.

1 February 2019 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
LLLi Li
Li Li
JKJing Kong
Jing Kong
CYChun-Hua Yao
Chun-Hua Yao
XLXiu-Feng Liu
Xiu-Feng Liu
JLJi-Hua Liu
Ji-Hua Liu

23 June 2022 in Phytotherapy Research
Verified
Journal Article
Closed access
MZMuqing Zhang
Muqing Zhang
JQJiaying Qi
Jiaying Qi
QHQianqian He
Qianqian He
MDMa Donglai
Ma Donglai
JLJing Li
Jing Li
LCLi Chu
Li Chu

11 September 2018 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
CGCai Gaojun
Cai Gaojun
LYLei Yu
Lei Yu
ZHZhiying Huang
Zhiying Huang
LLLi Li
Li Li
XFXingli Fu
Xingli Fu
Genetic and environment factors affect the occurrence and development of coronary artery disease (CAD). Proprotein convertase subtilisin/kexin type 9 (PCSK9), has been investigated extensively in the field of lipid metabolism and CAD. We performed this case-control study to investigate the relationship between serum PCSK9 levels and PCSK9 polymorphisms and lipid levels and CAD risk in a southern Chinese population. A hospital-based case-control study with 1, 096 subjects, including 626 CAD patients and 470 controls, were conducted. Genotyping of PCSK9 polymorphisms was performed using polymerase chain reaction-ligase detection reaction (PCR-LDR) method. The frequencies of the AA, AG and GG genotypes of PCSK9 E670G polymorphism were 90.58, 9.27, and 0.16% in the CAD patients, compared with 88.72, 10.85 and 0.43% in the controls, respectively. No R46L variant was detected in this population. There were no significant differences in genotype and allele frequencies of PCSK9E670G polymorphism between the CAD group and the controls. Serum lipid levels were not significantly different in carriers with the G allele and those with the AA genotype. The median (QR) of PCSK9 concentration was 1205.00 ng/l (577.28–1694.13 ng/l) in cases and 565.87 ng/l (357.17–967.50 ng/l) in controls, respectively. Compared with controls, CAD patients had significantly higher PCSK9 levels (z = 4.559, P < 0.001). After adjusting for age, gender, essential hypertension, diabetic mellitus, smoking and lipid profiles, PCSK9 levels remain significantly associated with increased CAD susceptibility (OR = 1.002, 95% CI = 1.001–1.002, P < 0.001). The correlation analyses showed that serum PCSK9 levels were positively associated with triglyceride (TG), Apo B and atherogenic index of plasma (AIP) levels in controls. No significant association between the PCSK9 E670G polymorphism and serum PCSK9 levels was observed in the CAD group and the controls. The present study shows that serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk in Southern Chinese Han population, and that serum PCSK9 levels are positively associated with AIP.

19 September 2018 in Molecules
Verified
Journal Article
Open access
PDF file
LLLi Li
Li Li
CSChen Shen
Chen Shen
YHYa-Xuan Huang
Ya-Xuan Huang
YLYa-Nan Li
Ya-Nan Li
XLXiu-Feng Liu
Xiu-Feng Liu
JLJi-Hua Liu
Ji-Hua Liu
The interaction between proprotein convertase subtilisin/kexin type 9 (PCSK9) and the low-density lipoprotein receptor (LDLR) is a promising target for the treatment of hyperc-holesterolemia. In this study, a new method based on competitive affinity and tag detection was developed, which aimed to evaluate potent natural inhibitors preventing the interaction of PCSK9/LDLR directly. Herein, natural compounds with efficacy in the treatment of hypercholesterolemia were chosen to investigate their inhibitory activities on the PCSK9/LDLR interaction. Two of them, polydatin (1) and tetrahydroxydiphenylethylene-2-O-glucoside (2), were identified as potential inhibitors for the PCSK9/LDLR interaction and were proven to prevent PCSK9-mediated LDLR degradation in HepG2 cells. The results suggested that this strategy could be applied for evaluating potential bioactive compounds inhibiting the interaction of PCSK9/LDLR and this strategy could accelerate the discovery of new drug candidates for the treatment of PCSK9-mediated hypercholesterolemia.

1 January 2024 in Canadian Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
YBYaning Biao
Yaning Biao
DLDantong Li
Dantong Li
ZYZhang Yi-xin
Zhang Yi-xin
JGJingmiao Gao
Jingmiao Gao
YXYi Xiao
Yi Xiao
LLLi Li
Li Li
Here, we presented the study of the molecular mechanisms underlying the action of Wulingsan (WLS) in rats with metabolic‐associated fatty liver disease (MAFLD) induced by a high‐fat diet (HFD). High‐performance liquid chromatography was employed to identify the chemical components of WLS. After 2 weeks of HFD induction, MAFLD rats were treated with WLS in three different doses for 6 weeks, a positive control treatment or with a vehicle. Lipid metabolism, liver function, oxidative stress, and inflammatory factors as well as pathomorphological changes in liver parenchyma were assessed in all groups. Finally, the expressions of autophagy‐related markers, adenosine monophosphate‐activated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR)/unc‐51‐like kinase‐1 (ULK1) signaling pathway‐related genes, and proteins in liver were detected. The results revealed that WLS significantly ameliorated liver injury, the dysfunction of the lipid metabolism, the oxidative stress, and overall inflammatory status. Furthermore, WLS increased the expressions of LC3B‐II, Beclin1, p‐AMPK, and ULK1, along with decreased p62, p‐mTOR, and sterol regulatory element‐binding protein‐1c levels. In conclusion, we showed that WLS is capable of alleviating HFD‐induced MAFLD by improving lipid accumulation, suppressing oxidative stress and inflammation, and promoting autophagy.